Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
eNq1mF1v2jAUhu/5FVHuSRpa2jIFqo21G1KrMlq0aTfIJIdiFuz02Oajv34OoRtMjroafBnbeX3s8/rxkeOr1TzzFoCCctb2o+DE94AlPKXsqe0PH2/ql/5VpxbPyILsDLsIToKo4XtJRoRo+0VvMAbCRPDj7vYz6P8B/U7Ni/l4BoncG6ckzYKvREzvSF6M8eIFp6k3BznladvPldy0erGQqKPoLDn+EjlJIA63Lbu9s9HZbnscFmL/oaoE4C1hT0ZRYFaaiUIEJrtEwhPHdUW8p1baVAxAcIUJ9Imc9pEvaAqpcYoJyQRYTTJZpg+AiwxkMYlRPJwlc2ElTmZkNYDnnjnoj7q3K1eyflKPLs7PWs2o0Wg1Lu2SiztbZc6CXkSYjKLTZuvirBkCC+dr/rKeg2Vu+hwlyRxlhYruvrEczYPw/Gb2UyryjKyDmchtt4og0d2A+vi7W0ixgkfUQMr0nv2jz1SWhe+MerjFhaOICxp1uWKygho3A9uN6HImYVWdUTvQydXWixTE8WRfODNDvq/GGU1skaaho0DI4aBXTbRjwuATETBEdzT4TlnKl+L4lNnNqqPo8w0ojaI5ptGo0bo8j5pN60P0U1uo4oa5VshzCDV/qDgEKz024YcCRbvSLPXqyaPZcVPn8IRkUFHp1C3Zon34Wpg5c7q7U1R2GEW/XD/a2uObAlw/bD6N0jRt/0msHXhd0FybsTLw91u7POFOamCFZnJMpczFhzBcLpfBlIi6IHqXggkenew7l6m7CtzJjV1WMCUdHYU+Lq+992XI9qS9dacfWqdu/9/Ww8Y5JCo4IBcllJ2hs3d9fBr/LVKdhd3fo4e7aTYFJZGUM1eFjhobFQ/jv84ru0ENiPvJhFa8iFT6Mg7L15hOLQ6Ll5hO7Tdwb+WG
p6qNhPTcA0p4Fd0S
Listen
